Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.54M | 56.76M | 56.01M | 50.11M | 45.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 263.46M | 250.64M | 230.86M | 209.10M | 188.19M |
| Operating Income | -263.46M | -250.64M | -230.86M | -209.10M | -188.19M |
| Income Before Tax | -243.61M | -293.25M | -273.79M | -253.75M | -235.66M |
| Income Tax Expenses | 178.00K | 446.00K | 393.00K | 268.00K | 268.00K |
| Earnings from Continuing Operations | -243.79 | -293.70 | -274.18 | -254.02 | -235.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -243.79M | -293.70M | -274.18M | -254.02M | -235.93M |
| EBIT | -263.46M | -250.64M | -230.86M | -209.10M | -188.19M |
| EBITDA | -262.83M | -250.00M | -230.20M | -208.43M | -187.53M |
| EPS Basic | -1.53 | -1.88 | -2.56 | -3.47 | -4.34 |
| Normalized Basic EPS | -0.96 | -0.91 | -1.33 | -1.90 | -2.45 |
| EPS Diluted | -1.53 | -1.88 | -2.56 | -3.47 | -4.34 |
| Normalized Diluted EPS | -0.96 | -0.91 | -1.33 | -1.90 | -2.45 |
| Average Basic Shares Outstanding | 637.49M | 629.34M | 516.45M | 387.59M | 258.93M |
| Average Diluted Shares Outstanding | 637.49M | 629.34M | 516.45M | 387.59M | 258.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
